Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer By Ogkologos - June 30, 2025 561 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the INAVO120 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection January 14, 2026 FDA Approves Pembrolizumab with Chemotherapy for Biliary Tract Cancer November 8, 2023 News digest – light-activated nanoparticles, Government’s obesity plans, tumour ‘glue’ and... July 11, 2020 After Battling Breast Cancer and Infertility, Mom Welcomes Miracle Baby November 25, 2020 Load more HOT NEWS Science Surgery: ‘How are children’s cancers different from adult’s cancers?’ A Robust, Durable Activity of Atezolizumab Observed in a Diverse Cohort... Protecting Your Skin From the Sun All Year: Why It’s Important... The Appraisal – Scientific disruption: what is it, and do we...
